| [1] |
Ellenson LH, ed. Blaustein′s pathology of the female genital tract[M]. New York: Springer, 2011: 360.
|
| [2] |
Silverberg SG, Kurman RJ, Nogales F, ed. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours[M]. Lyon: IARC, 2003: 221-232.
|
| [3] |
Kurman RJ, Carcangiu ML, Herrington CS, ed. WHO classification of tumours of female repro ductive organs. 4th ed[M]. Lyon: IARC, 2014.
|
| [4] |
Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion No. 631. Endometrial intraepithelial neoplasia[J]. Obstet Gynecol, 2015, 125(5): 1272-1278.
|
| [5] |
Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia[J]. J Clin Oncol, 2010, 28(5): 788-792.
|
| [6] |
Royal College of Obstetricians and Gynaecologists. Management of endometrial hyperplasia. Green-top guideline No. 67 RCOG/BSGE joint guideline[M]. London: RCOG Press, 2016.
|
| [7] |
吴成. 子宫内膜癌的筛查策略[J]．中国计划生育学杂志，2012, 20(10): 717-719.
|
| [8] |
Black A, Guilbert E, Costescu D, et al. Canadian contraception consensus (part 3 of 4): chapter 7--intrauterine contraception[J]. J Obstet Gynaecol Can, 2016, 38(2): 182-222.
|
| [9] |
冷旭，王敏，张淑兰，等. 不同方法获取子宫内膜进行组织学诊断的对照研究[J]. 中华妇产科杂志， 2013, 48(12) : 891-895.
|
| [10] |
Clark TJ, Voit D, Gupta JK, et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review[J]. JAMA, 2002, 288(13): 1610-1621.
|
| [11] |
Leitao MM Jr, Han G, Lee LX, et al. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk[J]. Am J Obstet Gynecol, 2010, 203(4): 349. e1-e6.
|
| [12] |
Costales AB, Schmeler KM, Broaddus R, et al. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia[J]. Gynecol Oncol, 2014 (135): 451-454.
|
| [13] |
Clark TJ, Voit D, Gupta JK, et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review[J]. JAMA, 2002, 288(13): 1610-1621.
|
| [14] |
Rotenberg O, Renz M, Reimers L, et al. Simultaneous endometrial aspiration and sonohysterography for the evaluation of endometrial pathology in women aged 50 years and older[J]. Obstet Gynecol, 2015, 125(2): 414-423.
|
| [15] |
Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group[J]. J Obstet Gynaecol Res, 1997, 23(3): 223-230.
|
| [16] |
Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of " untreated" hyperplasia in 170 patients[J]. Cancer, 1985, 56(2): 403-412.
|
| [17] |
Committee opinion No. 605: primary ovarian insufficiency in adolescents and young women[J]. Obstet Gynecol, 2014, 124(1): 193-197.
|
| [18] |
Amezcua CA, Lu JJ, Felix JC, et al. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia[J]. Gynecol Oncol, 2000, 79(2): 169-176.
|
| [19] |
Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and Meta analysis[J]. Am J Obstet Gynecol, 2012, 207(4): 266. e1-e12.
|
| [20] |
Emarh M. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study[J]. Arch Gynecol Obstet, 2015, 292(6): 1339-1343.
|
| [21] |
Park JY, Lee SH, Seong SJ, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin[J]. Gynecol Oncol, 2013, 129(1): 7-11.
|
| [22] |
Abu Hashim H, Zayed A, Ghayaty E, et al. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial[J]. J Gynecol Oncol, 2013, 24(2): 128-134.
|
| [23] |
Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women[J]. Ann Oncol, 2011, 22(3): 643-649.
|
| [24] |
Kill LM, Kapetanakis V, McCullough AE, et al. Progression of pelvic implants to complex atypical endometrial hyperplasia after uterine morcellation[J]. Obstet Gynecol, 2011, 117(2 Pt 2): 447-449.
|
| [25] |
American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for laparoscopic subtotal/supracervical hysterectomy (LSH)[J]. J Minim Invasive Gynecol, 2014, 21(1): 9-16.
|
| [26] |
中华医学会妇产科学分会妇科内分泌学组. 异常子宫出血诊断与治疗指南[J]. 中华妇产科杂志， 2014, 49(11): 801-806.
|
| [27] |
Kumar S, Bandyopadhyay S, Semaan A, et al. The role of frozen section in surgical staging of low risk endometrial cancer[J]. PLoS One, 2011, 6(9): e21912.
|
| [28] |
Moulder JK, Yunker A. Endometrial ablation: considerations and complications[J]. Curr Opin Obstet Gynecol, 2016, 28(4): 261-266.
|
| [29] |
Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival[J]. Gynecol Oncol, 2014, 132(1): 236-240.
|
| [30] |
Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells[J]. J Steroid Biochem Mol Biol, 2011, 126(3-5): 113-120.
|